Lifestyle behaviors, such as body mass index and smoking, were shown to have a greater predictive impact regarding development of psoriasis compared with genetic predisposition.
In determining risk of psoriasis development, lifestyle behaviors may garner greater predictive value vs genetic predisposition, according to study findings published in the Journal of the American Academy of Dermatology.
Characterized as an immune-related inflammatory skin disorder, psoriasis has been shown in prior research to be associated with certain genetic susceptibility. Genetic variants have been implicated in the pathogenesis of psoriasis, noted researchers, as well as several modifiable risk factors, including a high body mass index (BMI), smoking, physical activity, and dietary habits.
“Psoriasis can be triggered by both behavioral and genetic factors. Nonetheless, health behaviors and genetic risk factors have often been investigated separately,” they said. “Whether lifestyle is associated with the risk of psoriasis in the presence of different genetic risk levels remains unknown.”
Researchers conducted a prospective cohort study of data derived from the UK Biobank to investigate the gene-behavior interaction in association with incident psoriasis. Data from a total of 345,672 patients (mean [SD] age, 56.53 [8.06] years; 52% female) were included in the analysis.
Genetic risk was categorized into low, intermediate, and high groups, and lifestyle score comprising BMI, smoking, physical activity, and diet, were differentiated as ideal, intermediate, and poor. The study cohort included 2258 patients with incident psoriasis and 343,414 patients with no psoriasis.
“Within each genetic risk group, the risks of incident psoriasis associated with each lifestyle level were investigated and compared with the low genetic risk and ideal lifestyle group,” explained the study authors.
Overall, findings indicated that risk of incident psoriasis significantly increased in the poor vs ideal lifestyle groups (HR, 2.604; 95% CI, 2.042-3.319), and the high vs low genetic risk groups (HR, 1.342; 95% CI, 1.180-1.526).
The joint effect of genetic risk and lifestyle further showed that compared with the low genetic risk and ideal lifestyle group, the poor lifestyle and high genetic risk group was associated with a more than 4-fold increased risk of psoriasis (HR, 4.625; 95% CI, 2.920-7.348). No interaction between genetic risk and lifestyle was observed.
In response to the absence of interactions between genetic risk and lifestyle, researchers performed a population-attributable fraction (PAF) of both variables. In their findings, 32.2% (95% CI, 25.1%-38.6%) of new-onset psoriasis events during follow-up might have been prevented if all individuals would have adhered to ideal lifestyle, according to the PAF, whereas only 13.0% (95% CI, 3.2%-21.8%) of new-onset events would be reduced if all individuals were low genetic risk.
“To our knowledge, this study was the first to report the associations of combined health lifestyle and genetic risk for psoriasis,” concluded the study authors. “The results suggest the importance of a joint assessment of the risk of psoriasis for individuals—the establishment of an integrated ideal lifestyle for the prevention of psoriasis should be advocated.”
Reference
Shen M, Xiao Y, Jing D, et al. Associations of combined lifestyle and genetic risks with incident psoriasis: a prospective cohort study among UK Biobank participants of European ancestry. J Am Acad Dermatol. 2022 Apr 12;S0190-9622(22)00604-1. doi:10.1016/j.jaad.2022.04.006
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More